Who Generates More Revenue? United Therapeutics Corporation or Exelixis, Inc.

Revenue Race: United Therapeutics vs. Exelixis

In the competitive landscape of biotechnology, revenue generation is a key indicator of success. Over the past decade, United Therapeutics Corporation and Exelixis, Inc. have been at the forefront of this race. From 2014 to 2023, United Therapeutics consistently outperformed Exelixis, with revenues peaking at approximately 2.3 billion in 2023, marking an impressive 80% increase from 2014. Meanwhile, Exelixis showed remarkable growth, with revenues surging from a modest 25 million in 2014 to nearly 1.8 billion in 2023, a staggering 7,200% increase. This growth trajectory highlights Exelixis's rapid expansion in the biotech sector. Despite Exelixis's impressive growth, United Therapeutics maintained a steady lead, underscoring its established market presence. As the biotech industry continues to evolve, these two companies exemplify the dynamic nature of revenue generation and market competition.